Earnings Summary: Highlights of IDEXX’s Q3 2025 report

Medical device company IDEXX Laboratories, Inc. (NASDAQ: IDXX) on Monday reported higher revenues and earnings for the third quarter of fiscal 2025.

• Third-quarter revenue grew 13% year-over-year to $1.11 billion; sales rose 12% on an organic basis
• CAG Diagnostics recurring revenue increased 11% on a reported basis and 10% on an organic basis
• Livestock, Poultry, and Dairy revenue growth was 17% on a reported basis, and 14% organically
• Third-quarter earnings per share were $3.40, up 21% from last year; on a comparable basis, EPS growth is 15%
• The management raised its full-year revenue guidance range to $4.27-4.30 billion, or reported growth of 9.6-10.3%
• It also raised organic revenue growth guidance for FY25 to 8.8-9.5%, reflecting the operational performance benefits
• Reported operating margin outlook for the year has been raised to 31.6-31.8%
• The company updated its EPS outlook range to $12.81-13.01, incorporating a $0.33 increase at mid-point versus prior guidance